LONDON (dpa-AFX) - German biopharmaceutical company CureVac N.V. (CVAC) announced Wednesday that the first participant was dosed in a Phase 1 study of COVID-19 second-generation mRNA vaccine candidate
DGAP-News: CureVac / Schlagwort(e): Studienergebnisse/Studie CureVac: mRNA-basierter COVID-19-Impfstoffkandidat der zweiten Generation, CV2CoV, zeigt verbesserte Immunantwort und Schutzwirkung
GSK, CureVac’s next-gen COVID-19 jab generates positive preclinical data
14th May 2021
GlaxoSmithKline (GSK) and CureVac’s second generation COVID-19 vaccine, CV2CoV, has generated positive preclinical data, the companies announced yesterday.
Preclinical testing in a rat model showed that CV2CoV induces high levels of antigen production and strong, dose-dependent immune responses in vaccinated animals.
The data, published on the pre-print server bioRxiv, also showed that rats immunised with the second-generation jab demonstrated ‘fast onset’ of strong immune responses after their first dose.
On top of that, the serum of vaccinated animals showed significant cross-neutralisation against variants of concern, including those first discovered in Denmark (B.1.1.298), the UK (B.1.1.7) and South Africa (B.1.351).
LONDON (dpa-AFX) - Biopharmaceutical company CureVac N.V. (CVAC) announced Thursday that its second generation COVID-19 vaccine candidate, CvnCoV, demonstrated high immunogenicity against virus
Second-generation lead COVID-19 vaccine candidate, CV2CoV, developed in collaboration by CureVac and GSK CV2CoV mRNA shows high levels of antigen production in rat model Fast onset of strong neutralizing